FMC Corporation Reports 4% Revenue Decline and Increased Net Loss in Q1 2026

FMC Corporation reported a significant decline in its financial performance for the first quarter of 2026, with revenues totaling $758.6 million, a decrease of approximately 4% from $791.4 million in the same period last year. The decline was attributed to lower pricing pressures on key products, particularly in Latin America, and competitive market conditions affecting legacy core products. Gross margin also fell to $246.6 million, down from $316.7 million, reflecting a gross margin percentage of about 33%, compared to 40% in the prior year. The company recorded a net loss attributable to FMC stockholders of $281.3 million, a substantial increase from a loss of $15.5 million in the previous year.

The financial results were impacted by several factors, including a provision for income taxes of $112.1 million, which was influenced by an increase in the valuation allowance in Switzerland due to changes in the global earnings mix. Additionally, restructuring and other charges rose significantly to $77 million, primarily due to costs associated with Project Foundation, a comprehensive plan aimed at optimizing FMC's cost structure. The company also faced increased interest expenses, which rose to $64.8 million from $50.1 million, driven by higher domestic long-term debt balances.

FMC's operational metrics showed mixed results, with a notable increase in sales in the Europe, Middle East, and Africa (EMEA) region, which grew by approximately 13%. However, sales in Asia plummeted by 39%, largely due to pricing pressures from generic competition. The company reported a decrease in research and development expenses to $65.5 million, down 5% from the previous year, reflecting ongoing cost reduction efforts. The total employee headcount remained stable, but the company is focusing on restructuring initiatives that may impact future staffing levels.

Looking ahead, FMC plans to strengthen its balance sheet by reducing debt through asset sales, including the ongoing divestiture of its India commercial business, which is classified as held for sale. The company anticipates that the sale will conclude in 2026 and is expected to provide liquidity for debt repayment. FMC's strategic priorities for 2026 include enhancing the competitiveness of its core portfolio and managing the transition of its Rynaxypyr® active ingredient. Despite the challenges, the company remains committed to investing in new active ingredients and technologies to drive future growth.